What's in Baxalta now part of Shire's pipeline?

Baxalta now part of Shire has 26 drugs in our index: 12 marketed, 0 filed, 7 in Phase 3, 3 in Phase 2, 4 in Phase 1.

Which companies overlap with Baxalta now part of Shire's portfolio?

Top competitors by shared drug class: CSL Behring, Bayer, Pfizer, Biotest, Kedrion S.p.A..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/baxalta-now-part-of-shire.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Baxalta now part of Shire — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baxalta now part of Shire pipeline: 12 marketed, 0 filed, 7 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 7 Phase 3 3 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
RIXUBIS: Prophylaxis	RIXUBIS: Prophylaxis	marketed	Recombinant coagulation factor	Coagulation Factor IX (FIX)	Hematology
Recombinant factor IX	Recombinant factor IX	marketed	Recombinant clotting factor	Coagulation factor IX (F9)	Hematology
CUVITRU	CUVITRU	marketed			Immunology
RIXUBIS: On-Demand	RIXUBIS: On-Demand	marketed	Recombinant coagulation factor	Coagulation Factor IX (FIX)	Hematology
Recombinant Factor VIII (rAHF)	Recombinant Factor VIII (rAHF)	marketed	Recombinant clotting factor	Coagulation Factor VIII	Hematology
OBIZUR	OBIZUR	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII	Hematology
RIXUBIS	RIXUBIS	marketed			Other
Placebo: Human albumin 2.5%	Placebo: Human albumin 2.5%	marketed	Plasma volume expander; colloid		Critical Care; Hematology
ITI	ITI	marketed	Immune tolerance induction regimen		Hematology
ARALAST Alpha1-Proteinase Inhibitor	ARALAST Alpha1-Proteinase Inhibitor	marketed
Alpha1-Proteinase Inhibitor	Alpha1-Proteinase Inhibitor	marketed	Protease inhibitor (protein replacement therapy)	Neutrophil elastase (indirect target via AAT inhibition)	Pulmonology / Respiratory
KIOVIG	KIOVIG	marketed			Other

Therapeutic area mix

Hematology · 9
Immunology · 4
Other · 2
Hemophilia A · 1
Critical Care; Hematology · 1
Oncology · 1
Pulmonology / Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CSL Behring · 4 shared drug classes
Bayer · 3 shared drug classes
Pfizer · 2 shared drug classes
Biotest · 2 shared drug classes
Kedrion S.p.A. · 2 shared drug classes
Octapharma · 2 shared drug classes
Grifols Therapeutics LLC · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Baxalta now part of Shire:

Cite this brief

Drug Landscape (2026). Baxalta now part of Shire — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/baxalta-now-part-of-shire. Accessed 2026-05-17.